good and Tolga, morning Thanks everyone.
update amyloidosis, you clinical a by ATTR Let I'll me where patisiran, candidates, efforts on advancing three and as begin moment, in we are vutrisiran, in product our updating TTRscXX. stage
Xth. patisiran accepted been and by First, has Yvonne, delighted the application from as PDUFA supplemental for with date of that a for ATTR October standard drug the you've new amyloidosis FDA of review are we our heard a cardiomyopathy
RNAi FDA identified the to letter, acceptance If APOLLO-B placebo. study, type stated pivotal wild that file cardiomyopathy. this advisory that are given not to they and in is their for issues. based noted The patients potential life of which they quality demonstrated with extend review status This amyloidosis the patisiran allow filing agency application. the XX and to an the ATTR committee months of therapeutic In with many meeting functional also will us patients the hereditary have cardiomyopathy to on to any with ATTR improved planning approved, discuss benefits relative an hold
is efficacy progression. favorably treatment exploratory and can supported safety data encouraging profile patisiran also that an indicating The disease impact by
ATTR now amyloidosis details on filing global share some With with the I'd also in for accepted, plans like our cardiomyopathy. sNDA patisiran to
submit to early in an We planning Brazil are sNDA XXXX. in
This do study a combined market with of enrollment not obtaining to we anticipated the and vutrisiran of than other the access approval regions. the in label is pursue timelines However, expansion and in these earlier countries. result plan regulatory HELIOS-B for completion
efforts As we focus vutrisiran to sNDA ongoing in will an from a the positive study. assuming HELIOS-B results regions submitting result, our for other
APOLLO-B, in studying for on a as but outcomes is early mortality designed track As a a to primary CV We top all-cause HELIOS-B is events. line XXXX. endpoint reminder, population of and results remain recurrent share similar
after or study RTE, evaluating as the of been had HELIOS-A regimen dosing was randomized of performed main treatment you completed. have portion of the which a we extension the vutrisiran As know, biannual part
been every dosing we versus regimen if the has objective with XX months more Our mg to can regimen provide maintained already see excellent efficacy. a profile three convenient the of
results with month regimen the as through reporting The mg as primary well TTR randomized XX mg RTE line treatment nine. Today regimen of XX lowering endpoint safety profile. we of acceptable was of an biannual the versus quarterly the are top non-inferiority the extension
indeed As expected the TTR mg biannual of by regimen nine months. non-inferiority mean demonstrated XX reduction dosing over established was serum as
the towards serum of TTR some mg end interval very at XX recovery the months. note reduction did we in six of However, arm dosing the
the to XX% of XX% that regarding other knockdown. To XX regimen. on events mg cardiac, illustrate demonstrate or the In this, at with biannual patients knockdown safety regimen of mg signals whereas month XX% were quarterly on same acceptable XX% an words, of Vutrisiran patients did also biannual the patients continued XX% greater, regimen, achieved knockdown achieved hepatic XX degree six, observed. No not safety renal or get to TTR profile. of
known deaths of preexisting RTE five on mutations. drug and the was were the occurred six and the the to XX of considered quarterly one of the baseline the aggressive XX mg study there patient cardiomyopathy at occurred which majority In the biennial arm, with the in on in occurred None study. related out dropped notable study arm context mg patients after
the in made data the a efficacy regimen congress RTE, XX previously decision dosing not in strategic Despite into the Several present factors to XXXX. with results scientific regulatory forward submissions more and data played decision. planning mg these that safety early of we've planned. to biannual move details for as supportive vutrisiran on We're the from
the very of efficacy see the interval, end order to profile towards First, terms of TTR a patients. is which suboptimal recovery in maximal product achieve dosing believe observed biannual we in we serum of where pharmacology clamped for dynamics the
along an the heard physicians, given patients with you positive quarters subcutaneous in from very profile received greater compelling us Tolga, initial its therapeutic extremely it from the and on of exercise feedback the as advancing innovative commercial in performance to selectivity has quarterly its allows Second, two first strong AMVUTTRA market, offering. with dosing,
and clinic And RNAi on announce and targeting Platform for Phase potential silencing IKARIA in which ALN-TTRscXX investigational begun new molecule a based the possibility and more for proud dosing. is with a finally, therapeutic that we I'm dosing now TTR the X have potent TTR, durable an TTRscXX offers has study. to the annual it our entered
on we may advancing our As transformative innovation offer continued focus will profile. such, TTRscXX, a which
top XXXX. from expect study late results line We Phase the in X
deliver was our enrolled we offer differentiated treatment all In includes Phase A disease we programs, investigational inhibitors. for and on and believe with thrilled RNAi been X early KARDIA-X have addition our to we notable hypertension line antihypertensives We're our programs. believe mid-XXXX. existing track late also highlight clinical zilebesiran, which therapeutic great could the progress of stage our mid-stage making transform in of and from announced as including this results a highly RAS profile have study that to fully December top to
XXXX. KARDIA-X to end line around results forward look also top We at or year
We're act first to potential therapeutics amyloid tissues the intracellularly APP both differentiated cusp end, has angiopathy. treatment target the potential the and peptides. targeting cerebral also of delivery a Alzheimer's RNAi ALN-APP highly directed by disease in working To offer to to reduce to and where from disease important expand the disease-causing and RNAi ALN-APP, the the currently is extracellularly seeing antibodies of in upstream has investigational to for data to liver. Alzheimer's therapeutic we of approach and are which our development beyond on CNS, of that
an milestone, for just We these achieve if initial for data with believe overall positive be clinical particular CNS our platform show ALN-APP but important relevant to program, not that this clinically can top early knockdown RNAi that Phase target line safety on XXXX. the report study track the development. profile X to a further We and of dosing degrees remain supports with in from CNS in will results
innovation will type pipeline, underlying a submitted key highlights these X excited imminently. by expect just Phase expected growth product to have deliver are filing that driver organic represents to start years CTA few for our our These and with ALN-KHK broad a from engine innovative and sustainable To diabetes we X wrap the a for we're in a up highlights, come. in Alnylam driven
trial our have begun In X in Regeneron partners addition, ALN-PNP NASH. dosing at Phase a in of
let review that, it financial me With to milestones. now over upcoming to Jeff Jeff? and turn our results